KIM FOREST ENTERPRISE CO., LTD. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 39.35 TWD | -0.38% |
|
+5.92% | +6.64% |
| Mar. 14 | Kim Forest Enterprise Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
| Mar. 07 | Kim Forest Enterprise Co., Ltd.(TWSE:6645) added to Taiwan TAIEX Index | CI |
| Sales 2022 | 671M 20.58M | Sales 2023 | 415M 12.74M | Capitalization | 1.7B 52.1M |
|---|---|---|---|---|---|
| Net income 2022 | 43M 1.32M | Net income 2023 | -102M -3.13M | EV / Sales 2022 | 2.09 x |
| Net Debt 2022 | 1.67M 51.29K | Net Debt 2023 | 24.02M 737K | EV / Sales 2023 | 4.15 x |
| P/E ratio 2022 |
32.8
x | P/E ratio 2023 |
-16.6
x | Employees | - |
| Yield 2022 |
0.29% | Yield 2023 |
-
| Free-Float | 52.03% |
More Fundamentals
* Assessed data
More news
| 1 day | -0.38% | ||
| 1 week | +5.92% | ||
| Current month | +2.34% | ||
| 1 month | +6.06% | ||
| 3 months | +5.92% | ||
| 6 months | -12.75% | ||
| Current year | +6.64% |
1 week
37.80
42.00
1 month
37.1042.00
Current year
35.1047.40
1 year
29.2652.90
3 years
18.3754.76
5 years
8.69128.70
10 years
8.69128.70
| Managers | Title | Age | Since |
|---|---|---|---|
Hui E Chen
CEO | Chief Executive Officer | - | 05-06-30 |
Wen Ming Yang
DFI | Director of Finance/CFO | - | 13-12-01 |
Tao Peng Chen
CTO | Chief Tech/Sci/R&D Officer | - | 16-10-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Ming Sung Cheng
BRD | Director/Board Member | - | 20-06-28 |
Hui E Chen
CEO | Chief Executive Officer | - | 05-06-30 |
Pin Tsung Wu
BRD | Director/Board Member | - | 04-07-27 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-26 | 39.35 | -0.38% | 43,261 |
| 24-04-25 | 39.5 | -0.25% | 42,808 |
| 24-04-24 | 39.6 | -3.18% | 97,182 |
| 24-04-23 | 40.9 | +2.25% | 246,716 |
| 24-04-22 | 40 | +7.67% | 220,181 |
End-of-day quote Taiwan S.E., April 25, 2024
More quotes
KIM FOREST ENTERPRISE CO., LTD. is a Taiwan-based company mainly engaged in sale of biomedical products and provision of genetic testing and analysis services. The Company operates through two segments. The Biomedical Experiment Products segment is engaged in provision of laboratory equipment, reagents, supplies and equipment maintenance services. Main products include filter type microplate spectrophotometer, polymerase chain reaction (PCR) molecular biology experiment related equipment and reagents, equipment and reagents for separating cell, protein and nucleic acids, rapid DNA detection reagent and others. The Biotechnology and Genetic Testing segment is engaged in provision of whole genome sequencing (WGS) and whole exome sequencing(WES) tumor analysis services, RNA sequencing analysis, and new drug development system and check services.
Calendar
2024-05-20
- Annual General Meeting
| 1st Jan change | Capi. | |
|---|---|---|
| +6.64% | 60.58M | |
| -28.51% | 925M | |
| -20.60% | 128M | |
| -7.82% | 67.46M | |
| +14.87% | 61.68M | |
| +0.60% | 51.45M |
- Stock Market
- Equities
- 6645 Stock
